Correction
Pharmacology & Pharmacy
Yvette N. Lamb
Summary: A correction for this paper has been published and can be accessed at the provided link.
Review
Cell Biology
Sreerama Shetty, Steven Idell
Summary: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease with no effective treatments. Lung transplantation is limited to a small number of patients, therefore, new therapies targeting caveolin-1 could provide a promising treatment option for IPF patients.
Article
Radiology, Nuclear Medicine & Medical Imaging
Chi Wan Koo, James M. Williams, Grace Liu, Ananya Panda, Parth P. Patel, Livia Maria M. Frota Lima, Ronald A. Karwoski, Teng Moua, Nicholas B. Larson, Alex Bratt
Summary: QCT features and QCT feature-based ML models successfully differentiate interstitial lung diseases (ILDs). The performance of QCT-ML models outperforms a DL model in ILD classification. Further investigations are needed to determine the superior approach for ILD classification.
EUROPEAN RADIOLOGY
(2022)
Article
Immunology
Jer-Hwa Chang, Hsiao-Chi Chuang, George Hsiao, Tsung-Yun Hou, Ching-Chiung Wang, Shih-Chun Huang, Bo-Yi Li, Yueh-Lun Lee
Summary: Acteoside can suppress the production of proinflammatory mediators by dendritic cells and enhance the secretion of anti-inflammatory cytokines. It can also promote the generation of regulatory T cells through aryl hydrocarbon receptor activation. In a mouse model of allergic asthma, acteoside can reduce Th2-type cytokine levels, increase the levels of anti-inflammatory cytokines and the frequency of regulatory T cells, and ameliorate asthma symptoms and pulmonary inflammation.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Medicine, Research & Experimental
Nishan Deng, Xiaoshu Zuo, Qibin Lin, Tong Wang, Yun Li, Jieying Zhong, Haiyang Ni, Qianhui Chen, Xuhong Ding, Hongying Yu, Hanxiang Nie
Summary: Low-dose 5-FU treatment inhibits the development of asthma and improves Th2 cell response by inducing apoptotic cell death of moDCs.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Immunology
Nishan Deng, Xuxue Guo, Qianhui Chen, Linlin Liu, Shuo Chen, Ailing Wang, Ruiyun Li, Yi Huang, Xuhong Ding, Hongying Yu, Suping Hu, Yang Zhao, Xueqin Chen, Hanxiang Nie
Summary: The anti-F4/80 treatment alleviates Th2 cell responses in mice exposed to OVA or HDM, without affecting other immune cell types. It inhibits the expression of polarized markers of alternatively activated macrophages in lung tissues from OVA-induced asthmatic mice, and this inhibitory effect can be reversed upon adoptive transfer of lung IMs.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Gentaro Izumi, Hideki Nakano, Keiko Nakano, Gregory S. Whitehead, Sara A. Grimm, Michael B. Fessler, Peer W. Karmaus, Donald N. Cook
Summary: This study identified a subpopulation of cDCs in the lung of mice that can promote Th17 differentiation, showing a stepwise developmental progression from immature Ly-6C(+)Ly-6A/E+ cDC2 to mature cDC2. Through single cell RNA sequencing and adoptive transfer experiments, the researchers found that different stages of maturation and phenotype of mouse lung DC can promote Th17 or Th2 CD4(+) T cell differentiation.
NATURE COMMUNICATIONS
(2021)
Article
Immunology
Wenjing Gu, Suyu Guo, Jiahui Zhang, Xinxing Zhang, Zhichao Sun, Zhengrong Chen, Li Huang
Summary: Asthma is an inflammatory disease in which Th2 differentiation and dendritic cells (DCs) play important roles. Highly expressed March1 can promote Th2 differentiation induced by DCs through facilitating OX40L expression and contribute to the development of asthma. These findings might provide new insights into the treatment of asthma.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Respiratory System
Xi Zhan, Yingzhen Du, Jiang Luo, Yifan Que, Chao Hu, Lili Xu, Zhen Wang, Yanbing Wu, Mulan Jin, Chunming Zheng, Yanhong Gao, Christopher Chang, Hongxia Li, Zhaohui Tong, Guogang Xu
Summary: Fibrotic hypersensitivity pneumonitis should be considered in the differential diagnosis of pulmonary fibrosis. Pathological characteristics of fibrotic hypersensitivity pneumonitis can be demonstrated using TBLC, which is recommended as an alternative diagnostic technique that may improve the specificity of hypersensitivity pneumonia detection. Usual interstitial pneumonia (UIP) is the most frequent pathological finding.
CLINICAL RESPIRATORY JOURNAL
(2023)
Review
Gastroenterology & Hepatology
Jonaid Ahmad Malik, Mohammad Adeel Zafar, Taruna Lamba, Sidhanta Nanda, Mohammad Affan Khan, Javed Naim Agrewala
Summary: This article discusses the relationship between aging, gut microbiome, and dendritic cells (DCs), emphasizing the importance of age-related gut microbiome changes and DC function for the overall health and immune response in elderly individuals.
Article
Critical Care Medicine
Juergen Behr, Antje Prasse, Michael Kreuter, Johannes Johow, Klaus F. Rabe, Francesco Bonella, Reiner Bonnet, Christian Grohe, Matthias Held, Heinrike Wilkens, Peter Hammerl, Dirk Koschel, Stefan Blaas, Hubert Wirtz, Joachim H. Ficker, Wolfgang Neumeister, Nicolas Schoenfeld, Martin Claussen, Nikolaus Kneidinger, Marion Frankenberger, Simone Hummler, Nicolas Kahn, Silke Tello, Julia Freise, Tobias Welte, Petra Neuser, Andreas Guenther
Summary: This multicentre, double-blind, randomised, placebo-controlled trial aimed to evaluate the efficacy and safety of pirfenidone in patients with progressive fibrotic interstitial lung diseases. Results after 48 weeks showed a significantly lower decline in FVC % predicted in the pirfenidone group compared to placebo, suggesting that adding pirfenidone to existing treatment might attenuate disease progression in these patients.
LANCET RESPIRATORY MEDICINE
(2021)
Review
Respiratory System
Carlos A. C. Pereiraa, Soraya Corderoa, Ana Carolina Resendea
Summary: Many progressive fibrosing interstitial lung diseases (PF-ILDs) share mechanisms that result in a fibrosing phenotype. In Brazil, the most common PF-ILDs are chronic hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, unclassified ILD, and connective tissue diseases. Diagnosis of the disease causing fibrosis is critical for appropriate treatment. Antifibrotic drugs like nintedanib and pirfenidone have shown promise in treating PF-ILD.
JORNAL BRASILEIRO DE PNEUMOLOGIA
(2023)
Review
Biochemistry & Molecular Biology
Francesco Amati, Anna Stainer, Marco Mantero, Andrea Gramegna, Edoardo Simonetta, Giulia Suigo, Antonio Voza, Anoop M. Nambiar, Umberto Cariboni, Justin Oldham, Philip L. Molyneaux, Paolo Spagnolo, Francesco Blasi, Stefano Aliberti
Summary: Interstitial lung diseases are a complex group of diseases with unclear causes and mechanisms of progression. Recent research suggests that the lung microbiome may play a role in the development and progression of these diseases. However, the specific mechanisms are not yet understood. This review aims to discuss the role of altered lung microbiome in various interstitial lung diseases. Understanding the interaction between the host and microbiome in the lungs is a priority for research on these diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Critical Care Medicine
Simon L. F. Walsh, John A. Mackintosh, Lucio Calandriello, Mario Silva, Nicola Sverzellati, Anna Rita Larici, Stephen M. Humphries, David A. Lynch, Helen E. Jo, Ian Glaspole, Christopher Grainge, Nicole Goh, Peter M. A. Hopkins, Yuben Moodley, Paul N. Reynolds, Christopher Zappala, Gregory Keir, Wendy A. Cooper, Annabelle M. Mahar, Samantha Ellis, Athol U. Wells, Tamera J. Corte
Summary: This study evaluated the prognostic accuracy of a deep learning algorithm for predicting outcomes in patients with fibrotic lung disease using high-resolution computed tomography (HRCT) data. The results showed that this algorithm outperformed expert radiologist evaluation and guideline-based histologic pattern in predicting survival. It has the potential to be a useful tool in characterizing fibrotic lung disease in a multidisciplinary approach. Further research is needed to investigate its utility as a decision support system when interstitial lung disease expertise is unavailable.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Fernanda Gubert, Jaqueline Soares da Silva, Juliana F. Vasques, Renata Guedes de Jesus Goncalves, Robertta Silva Martins, Mauro Paes Leme de Sa, Rosalia Mendez-Otero, Gisele Zapata-Sudo
Summary: Stem cell therapy shows promising potential as an alternative approach to treat heart diseases, with multipotent stem cells sourced from bone marrow, adipose tissue, umbilical cord, and placenta commonly used in clinical trials. Therapeutic use of these cells aims to reduce cardiac fibrosis and inflammation, preventing abnormal cardiac remodeling and dysfunction.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)